Altimmune Secures $225M, Advances Pemvidutide for Liver Diseases

Altimmune secures $225M, boosting cash to $535M, as they prepare for Phase 3 MASH trial. Pemvidutide, their lead candidate, is set to start global Phase 3 PERFORMA study in H2 2022. With FDA & EMA approval, theyre partnering with a top CRO for rapid site activation. Pemvidutides UPORT tech reduces GI side effects, showing strong efficacy in Phase 2 IMPACT data. Investors and docs are confident, with top-line AUD data and RESTORE enrollment expected Q3 2022. Altimmune aims to deliver pemvidutide to liver patients, targeting real value in the future. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/58f2b5157abc7e37